-- The London Proteomics Discussion Group --
Proteomics seminar series for the South East

Next Webinar LPDG-YPIC Mini Challenge
Proteomics seminar series for the South East
Methods Challenge
---Registration is free---

About the LPDG

We are a free, local proteomics seminar series in the South East,
with a focus towards networking, discussion and supporting early career researchers.

The LPDG...

was founded to bring together the large community of proteomics scientists all working in and around London. We aim to provide a space for discussion, with a focus on methods and early career researchers (two fundamental building blocks of good research!), on all topics related to proteomics. The meetings comprise of research talks framed by a proteomics methods challenge, lunch, refreshments and pizza - they are free to attend thanks to sponsorship.

Meeting Dates:

Next Meeting


These seminars would not be possible without our amazing sponsors.
If you are interested in sponsoring an LPDG seminar,
please get in touch at sponsor@londonproteomics.co.uk

LPDG-YPIC Mini Challenge

The LPDG have teamed up with YPIC to produce a proteomics-challenge with Prize money sponsored by Matrix Science. To find out more and view the current challenge,

click here!

Webinar Programme

The Role of Proteomics in: Dementia Research (in collaboration with UKDRI)

07th May 2021 14:00 GMT

Jeffrey Savas

Pulse-chase proteomics of the App knock-in mouse models of amyloid pathology reveals synaptic dysfunction originates in presynaptic terminals

Alzheimer’s disease (AD) is an incurable brain disorder that currently debilitates millions of people world-wide. Historically, the etiological model has been that early alterations at synapses cause changes in the activity of neuronal circuits, which occur many years prior to the presentation of clinically impaired cognition. Consistently, synapse loss represents an important and early feature of AD that correlates with the severity of dementia. The mechanisms leading to synaptic dysfunction and loss are not fully understood and both direct and indirect effects of Abeta peptides and Tau pathology are recognized as key drivers. Our team has recently discovered that there is impaired protein degradation selectively associated with APP KI axon terminals that results in elevated abundance of synaptic vesicle associated proteins in early stages of AD pathology. Intriguingly, we observe a relationship between these observations and the effects of the atypical antiepileptic drug levetiracetam that is currently the subject of several Phase II clinical trials for AD. Our preliminary studies demonstrated that levetiracetam selectively normalizes SV endocytosis machinery abundance and restores non-amyloidogenic processing of APP which is anti-correlated to our disease progression observations. Thus we have uncovered a potential mechanism that may explain the therapeutic benefits of levetiracetam as well as targets for future therapeutic intervention. In this seminar, I will summarize these findings and describe our ongoing and future research.


Seth Grant

Dissecting synapse proteome complexity and synapse diversity

Prior to proteomic studies, synapses were considered to be relatively simple devices built from a handful of proteins. Proteomic studies of excitatory synapses across a range of vertebrate species have revealed a remarkable complexity with several thousand highly conserved proteins. This knowledge has had a profound impact on our understanding of human disease with mutations in hundreds of synapse genes causing over 130 brain disorders and has been used in many studies including those revealing schizophrenia is a synaptic disorder. Spatial proteomics has revealed that brain regions have different composition, which informs on the functional specialisation of brain regions and why diseases target those regions. We have developed methods to understand the differences in synapse protein composition at single-synapse resolution on a brain-wide scale in the mouse (Zhu, Cizeron, Qiu et al, Neuron 2018; Cizeron et al, Science 2020) and found unexpectedly high synapse diversity, which is described by the molecular composition and morphological characteristics of individual synapses. Data driven analysis of brain-wide data has enabled is to create a catalogue of excitatory synapse types and subtypes, which describes the synaptome. Every synapse type/subtype has a particular spatial distribution producing the synaptome architecture of the brain and this architecture changes across the lifespan, producing the Lifespan Synaptome Architecture. We have shown the synaptome architecture is important for physiological properties, structural and functional connectome properties and is reprogrmmed in genetic diseases. Single synapse proteome studies offer a new way to understand neurodegenerative and other brain disorders.


Event Speakers

Would you like to present at an LPDG meeting? Email: speaker@londonproteomics.co.uk
Research presentations from:

Dr Jeffrey Savas
Dr Jeffrey Savas
Dr Jeffrey Savas Department of Neurology
Northwestern University Feinberg School of Medicine

The overarching goal of Dr Savas's research is to determine how protein mishandling contributes to synaptic dysfunction, neurodegeneration, and aging. Preliminary findings show that presynaptic terminals represent pioneering sites of dysfunction during the early stages of Alzheimer’s disease (AD) like pathology (Hark et al. Cell Systems (2021). To determine the specific synapses with altered proteostasis he will use recently developed synaptic biotinylation probes. If successful, this research could provide a new understanding of the proteins responsible impaired synaptic transmission in AD.

Prof Seth Grant
Prof Seth Grant
Prof Seth Grant Centre for Clinical Brain Sciences
University of Edinburgh

Seth Grant is Professor of Molecular Neuroscience at the Centre for Clinical Brain Sciences, Edinburgh University, and a Fellow of the Royal Society of Edinburgh. His seminal work on the genetics of cognition, synapse proteomics and synaptopathies has earned international awards, most recently the 2020 FENS EJN Award. As a UK DRI Associate Member, Prof. Grant leads the Synapse Biology research theme at DRI Edinburgh and collaborates with DRI Imperial College on Alzheimer’s disease pathology as part of the Multi-‘omics Atlas Project. His current research provides insights into the mechanisms of memory and learning in healthy ageing and neurological disease.

Dr Blanca Diaz-Castro
Dr Blanca Diaz-Castro
Dr Blanca Diaz-Castro
Guest Chair
University of Edinburgh

Dr Blanca Díaz-Castro joined Edinburgh University in October 2019 as a UK DRI programme leader. She obtained her PhD degree at the University of Seville and after a brief stay at Northwestern University, completed her postdoctoral research at University of California. Her research is centred on the study of molecular and cellular aspects of astrocyte biology that contribute to neuronal function in health and disease. She applies her expertise to understand how blood brain barrier cells communicate and act as a bridge between the periphery and the brain.




Here is a list of answers to frequently asked questions for speakers, delegates and sponsors

If you still have unanswered questions after reading this page, wish to present a talk, suggest a venue or sponsor a meeting, please contact us.

Organising Committee

The organising committee is made up of early and "not-so-early" career scientists
from academia and industry.
If you are interested in joining the committee, please get in touch.

Dr Harvey Johnston
Dr Harvey Johnston Chairperson, Founder

After my PhD in blood plasma cancer proteomics I moved to the Cancer Proteomics Group at UCL. I founded the LPDG as a focus group for the SE. I am currently at the Babraham Institute investigating protein degradation pathways using proteomics.

Dr Harry Whitwell
Dr Harry Whitwell Communications Officer

I am a post doc at ICL, developing mass spectrometry and data analysis methodology for the study of protein PTMs, in particular methylation. My research is multidisciplinary, using chemistry, bioinformatics and biology. For more info, click here.

Dr Lukas Krasny
Dr Lukas Krasny Secretary

I am a post-doc at the ICR in Paul Huang’s group. My research interest is in extracellular matrix remodelling during cancer progression. From an analytical point of view, I am interested in protein quantification by DIA mass spectrometry.

Dr Roberto Buccafusca
Dr Roberto Buccafusca Treasurer

I manage an MS lab at QMUL. I graduated from Drexel University (USA) in Biomedical Science, completing my PhD work at Harvard University. After a long stint in the private sector, I re-joined academia here in the UK researching lipidomics and proteomics.

Danai Kati
Danai Kati
Danai Kati Committee Member

Danai studied biology and biomedical sciences in Greece. She has worked in numerous labs in England, Singapore, the Netherlands and Greece. Now she is focusing on her PhD at UCL in Primary Biliary Cholangitis analyzing human samples using Mass spectrometry.

Suniya Khatun
Suniya Khatun Committee member

I am a PhD student at UCL on the CellX project in the Thalassinos Lab studying competition in cellular populations using mass spectrometry-based proteomics.

Dr Daniel Conole
Dr Daniel Conole Committee member

Daniel is a post-doc in the lab of Prof. Ed Tate at Imperial College London. His research interests lie in the use of chemical proteomics for better understanding of drug targets, protein function, and post-translational modification dynamics.

Tom Ruane
Tom Ruane Committee member

Tom works for SCIEX in the London region helping customers with MS and 'OMICS applications. He gained an interest in MS from working with Prof Roy Goodacre, Manchester Institute of Biotech. applying -omics and chemometric approaches for rapid food authenticity determination.

Joanna Kirkpatrick
Dr Joanna Kirkpatrick
Dr Joanna Kirkpatrick Committee member

Joanna Kirkpatrick
Crick Insitute

London and the South East
United Kindgom

Please email with any questions.
Particularly welcome are venue suggestions,
speaker suggestions or if you are thinking of sponsoring a meeting.

This seminar series is run by volunteers from academia and industry. We will try to reply to your email as quickly as possible, but please allow at least 5 days.